Compare Open Text Corporation (OTEX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Open Text Corporation vs BIO-TECHNE Corp — how do they compare? Open Text Corporation trades at $23.37 (market cap $5.62B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 2× Open Text Corporation's market cap, and Open Text Corporation pays the higher dividend (4.84%). Which is the better fit depends on your goals — on Pluang, investors hold Open Text Corporation for 23 Days and BIO-TECHNE Corp for 63 Days on average.
| OTEX | TECH | |
|---|---|---|
Market Cap | $5.62B | $11.37B |
Volume | 1,217,244 | 3,153,511 |
Sector | Technology | Health |
52-Week High | $39.69 | $72.61 |
52-Week Low | $20.01 | $43.31 |
Typical Hold Time | 23 Days | 63 Days |
Enterprise Value | $10.64B | $11.40B |
Dividend Yield | 4.84% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OpenText (OTEX) trades at $23.14, up 1.89% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with a P/E of 8.97 and consistent earnings beats, including Q2 2026 EPS of $1.23 beating expectations by 20.6%. Recent debt refinancing activities and a strategic AI partnership with Cohere highlight management's focus on growth and financial flexibility.
OTEX presents a compelling value opportunity with discounted valuation multiples and improving cloud momentum, though elevated debt levels and competitive pressures remain key risks. Analyst consensus targets $28.30 (22% upside) with 42% buy ratings, suggesting cautious optimism for the software company's transformation efforts.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
